Plotkin Lilian I, Manolagas Stavros C, Bellido Teresita
Division of Endocrinology and Metabolism, The Center for Osteoporosis and Metabolic Bone Diseases, The Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, 4301 West Markham, Mail Slot 587, Little Rock, AR 72205, USA.
Bone. 2006 Sep;39(3):443-52. doi: 10.1016/j.bone.2006.02.060. Epub 2006 Apr 19.
Bisphosphonates induce osteoclast apoptosis, thereby decreasing bone resorption and reducing the rate of bone remodeling. Earlier work from our group and others has demonstrated that, additionally, bisphosphonates prevent osteoblast and osteocyte apoptosis in vivo and in vitro, raising the possibility that perhaps part of their anti-fracture efficacy may result from preserving the integrity of the osteocyte network and prolonging the working time of bone forming cells. Whereas induction of osteoclast apoptosis results from inhibition of the mevalonate pathway or from conversion to toxic ATP analogs, prevention of osteoblastic cell apoptosis is mediated by connexin43 hemichannel opening and activation of the extracellular signal-regulated kinases (ERKs). We examined here the ability of several bisphosphonates, including novel analogs, to exert these two effects. All 16 bisphosphonates studied inhibited etoposide-induced apoptosis of MLO-Y4 osteocytic cells and osteoblastic cells derived from calvaria, with EC50 between 10(-12) and 10(-10) M. On the other hand, only 10 analogs induced apoptosis of RAW-264.7-cell-derived osteoclasts. Each of the 6 bisphosphonates that lack pro-apoptotic activity in osteoclasts but retain anti-apoptotic activity in osteoblasts and osteocytes has a structural-related analog that is active in both cell types. These findings indicate that the structural prerequisites for the anti-apoptotic effect of bisphosphonates on cells of the osteoblastic lineage are less stringent than the ones required to induce osteoclast apoptosis and confirm that bisphosphonates act on the two cell types by distinct mechanisms. Preservation of osteoblast and osteocyte viability without inducing osteoclast apoptosis by these bisphosphonates analogs opens new possibilities for the treatment of bone fragility in conditions in which a decrease in bone remodeling is not desirable.
双膦酸盐可诱导破骨细胞凋亡,从而减少骨吸收并降低骨重塑速率。我们团队及其他团队早期的研究表明,此外,双膦酸盐在体内和体外均可防止成骨细胞和骨细胞凋亡,这增加了一种可能性,即其部分抗骨折疗效可能源于维持骨细胞网络的完整性以及延长骨形成细胞的工作时间。破骨细胞凋亡的诱导是由于甲羟戊酸途径的抑制或转化为有毒的ATP类似物,而成骨细胞凋亡的预防则是由连接蛋白43半通道开放和细胞外信号调节激酶(ERK)的激活介导的。我们在此研究了几种双膦酸盐(包括新型类似物)发挥这两种作用的能力。所研究的全部16种双膦酸盐均抑制依托泊苷诱导的MLO - Y4骨细胞和成颅盖骨来源的成骨细胞凋亡,半数有效浓度(EC50)在10^(-12)至10^(-10) M之间。另一方面,只有10种类似物可诱导RAW - 264.7细胞来源的破骨细胞凋亡。在破骨细胞中缺乏促凋亡活性但在成骨细胞和骨细胞中保留抗凋亡活性的6种双膦酸盐中的每一种都有一种在两种细胞类型中均有活性的结构相关类似物。这些发现表明,双膦酸盐对成骨细胞谱系细胞抗凋亡作用的结构先决条件不如诱导破骨细胞凋亡所需的条件严格,并证实双膦酸盐通过不同机制作用于这两种细胞类型。这些双膦酸盐类似物在不诱导破骨细胞凋亡的情况下保持成骨细胞和骨细胞活力,为治疗不希望骨重塑减少的骨脆性疾病开辟了新的可能性。